EGFR and non-small cell lung carcinoma: They also demonstrated that the existence of pretreatment T790M in EGFR-TKI naïve NSCLC patients predicted shorter EGFR-TKI response duration [20], indicating that NGS might be a useful tool for the prediction of the efficacy of EGFR-TKI.